Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : ahhaha's ahs -- Ignore unavailable to you. Want to Upgrade?

To: ahhaha who wrote (23540)	6/17/2013 3:30:01 PM
From: Lhn5	Read Replies (1) \| Respond to of 24758

They have met with some success with Dacogen. I am not in a position to evaluate the chances of success with these other 2 drugs in p1 and p2. They have cash now but might need more before another product is approved and selling. <<On July 20, 2011, we completed the acquisition of all of the outstanding shares of Astex Therapeutics Limited ("ATL"), a privately held UK-based biotechnology company with particular expertise in fragment-based drug discovery. We agreed to pay deferred consideration of $30 million in stock, cash, or a combination of stock and cash, to be determined at the discretion of the Company, no later than 30 months after the closing of the acquisition (January 2014). We made the first payment of $10 million in cash in February 2012, paid the second installment of $2.3 million in cash in August 2012, and paid the third installment of $2.9 million in cash in February 2013. >>n From last 10Q It also looks like they owe ATL another 15 million in cash and/or stock by year end.